The Asia-Pacific CDMO Market size is estimated at USD 71.60 billion in 2024, and is expected to reach USD 108.17 billion by 2029, growing at a CAGR of 8.60% during the forecast period (2024-2029).
The Asia-Pacific CDMO (contract development and manufacturing organization) market is poised for substantial growth in 2024 and beyond. This growth can be attributed to escalating pharmaceutical demands, increasing emphasis on R&D, and the growing trend of outsourcing drug development and manufacturing.
The Asia-Pacific CDMO Market is fragmented because of the presence of major players like Catalent Inc., Jubilant Biosys Ltd, Samsung Biologics, Boehringer Ingelheim Group, and WuXi Biologics. The other players are adopting acquisition and partnership strategies to enter the market and expand their offerings.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook